AstraZeneca plans to shutter lab, ax staffers

AstraZeneca ($AZN) is shuttering a lab in Devon, U.K., saying that it will now outsource work done to test the environment impact of drugs. The pharma giant has been undergoing a major restructuring, its third reorganization in recent years. The lab employs 71 people. An AstraZeneca exec says they plan to "support" the workers in coming months and would prefer to see the facility remain open. Release

Suggested Articles

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.